Read Mosby's 2014 Nursing Drug Reference Online
Authors: Linda Skidmore-Roth
Canada only Side effects:
italics
= common;
bold
= life-threatening
Nurse Alert
(lir′a-gloo′tide)
Victoza
Func. class.:
Antidiabetic agent
Chem. class.:
Incretin mimetics
Improved glycemic control and potential weight loss via activation of the glucagon-like peptide-1 (GLP-1) receptor
Type 2 diabetes mellitus in combination with diet/exercise
Hyper-sensitivity
Black Box Warning:
Medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), thyroid cancer
Precautions:
Breastfeeding, children, geriatric patients, alcoholism, burns, cholelithiasis, type 1 diabetes mellitus, ketoacidosis, diarrhea, fever, gastroparesis, hepatic/renal disease, hypoglycemia, infection, pancreatitis, surgery, thyroid disease, trauma, vomiting
• Adult:
SUBCUT
0.6 mg/day × 1 wk, then increase to 1.2 mg/day, max 1.8 mg/day
Available forms:
Solution for injection 18 mg/3 ml pre-filled pen
•
Give subcut only, inspect for particulate matter, discoloration; do not use if unusually viscous, cloudy, discolored, or if particles present; give daily anytime, without regard to meals; pen needles must be purchased separately, use Novo Nordisk needle; prior to first use, prime, see manual for directions; give in thigh, abdomen, or upper arm; lightly pinch fold of skin, insert needle at 90-degree angle (45-degree angle if thin), release skin; aspiration is not needed, give over 6 sec, rotate injection sites
•
If dose is missed, resume once-daily dosing at next scheduled dose
CNS:
Dizziness, headache
CV:
Hypertension
ENDO:
Hypoglycemia
EENT:
Sinusitis
GI:
Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, nausea, vomiting,
pancreatitis
INTEG:
Angioedema,
erythema, injection site reaction, urticaria
MS:
Back pain
SYST:
Antibody formation, infection, influenza,
secondary thyroid malignancy, anaphylaxis
Increase:
hypoglycemic reactions—angiotensin II receptor antagonists, ACE inhibitors, other antidiabetics, β-blockers, dexfenfluramine, fenfluramine, disopyramide, FLUoxetine, fibric acid derivatives, mecasermin, MAOIs, octreotide, pegvisomant, salicylates
Increase:
hyperglycemic reactions—protease inhibitors, phenothiazines, baclofen, atypical antipsychotics, corticosteroids, cycloSPORINE, tacrolimus, carbonic anhydrase inhibitors, dextrothyroxine, diazoxide, phenytoin, fosphenytoin, ethotoin, isoniazid, INH, niacin, nicotine, estrogens, progestins, oral contraceptives, growth hormones, sympathomimetics
Increase or decrease:
hypoglycemic reactions—androgens, bortezomib, quinolones, cloNIDine, alcohol, lithium, pentamidine
Increase or decrease:
effects of—torvastatin, acetaminophen, griseofulvin
Protein binding (98%); half-life 12-13 hr; binds to albumin, then released into circulation; peak 8-12 hr; body weight significantly affects pharmacokinetics
Black Box Warning:
Thyroid C-cell tumors; monitor during treatment
•
Hypoglycemic reactions
that may occur soon after meals: hunger, sweating, weakness, dizziness, tremors, restlessness, tachycardia
•
Hypersensitivity to this product
•
Serum glucose, A1c, CBC during treatment
•
Stress:
those diabetic patients exposed to stress, surgery, fever, infections may require insulin administration temporarily
Serious skin reactions:
angioedema, pancreatitis, secondary thyroid malignancy
•
Storage: do not store pen with needle attached; avoid direct heat and sunlight; discard 30 days after first use; after first use may be stored at room temp or refrigerated, do not freeze
•
Therapeutic response: stable and improved serum glucose, A1C, weight loss
•
About symptoms of hypo/hyperglycemia, what to do for each; to have glucagon emergency kit available; to carry a carbohydrate source at all times
•
About side effects associated with therapy, such as nausea and vomiting; that upward dose titration can be delayed or ignored, depending on tolerance
•
That diabetes is a lifelong illness; that product does not cure disease and must be continued on a daily basis
•
To carry emergency ID with prescriber’s phone number and medications taken
•
To continue with other recommendations: diet, exercise, hygiene
•
To test blood glucose using a blood glucose meter
•
To avoid other medications, herbs, supplements unless approved by prescriber
To report serious skin effects, abdominal pain with nausea/vomiting
•
Provide patient with written instructions if self-administration is ordered
Canada only Side effects:
italics
= common;
bold
= life-threatening
Nurse Alert
(lis-dex′am-fet′a-meen)
Vyvanse
Func. class.:
CNS stimulant
Chem. class.:
Amphetamine
Increases release of norepinephrine, dopamine in cerebral cortex to reticular activating system
Attention-deficit/hyperactivity disorder (ADHD)
Breast-feeding, hyperthyroidism, hypertension, glaucoma, severe arteriosclerosis, CV disease, hypersensitivity to sympathomimetic amines
Black Box Warning:
Substance abuse
Precautions:
Pregnancy (C), children <6 yr, Gilles de la Tourette’s disorder, depression, anorexia nervosa, psychosis, seizure disorder, suicidal ideation, MI, heart failure, alcoholism, aortic stenosis, bipolar disorder
• Child 6-12 yr:
PO
30 mg/day, may increase by 10-20 mg/day at weekly intervals, max 70 mg/day
Available forms:
Caps 30, 50, 70 mg
•
Give daily in
AM
•
Without regard to meals
•
Caps: may take whole or opened and contents dissolved in water
CNS:
Hyperactivity, insomnia, restlessness, talkativeness
, dizziness, headache, dysphoria, irritability, aggressiveness, CNS tumor, dependence, addiction, mild euphoria, somnolence, lability, psychosis, mania, hallucinations, aggression
CV:
Palpitations, tachycardia
, hypertension, decrease in heart rate,
dysrhythmias,
MI,
cardiomyopathy
EENT:
Blurred vision, mydriasis, dyplopia
ENDO:
Growth inhibition
GI:
Anorexia
, dry mouth, diarrhea, weight loss
GU:
Impotence, change in libido
INTEG:
Urticaria,
angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis
Metabolized by liver; urine excretion pH dependent; crosses placenta, breast milk; half-life <1hr
Hypertensive crisis: MAOIs or within 14 days of MAOIs
Increase:
serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRIs, serotonin-receptor agonists
Increase:
lisdexamfetamine effect—acetaZOLAMIDE, antacids, sodium bicarbonate, urinary alkalinizers
Increase:
CNS effect—haloperidol, tricyclics, phenothiazines, modafinil, meperidine, PHENobarbital, phenytoin
Increase:
CNS stimulation—melatonin
Decrease:
absorption of phenytoin
Decrease:
lisdexamfetamine effect—ascorbic acid, ammonium chloride, urinary acidifiers
Decrease:
effect of—adrenergic blockers, antidiabetics
•
Serotonin syndrome: St. John’s wort
Increase:
stimulant effect—khat, melatonin, green tea, guarana
Decrease:
stimulant effect—eucalyptus
Increase:
amine effect—caffeine
•
VS, B/P; product may reverse antihypertensives; check patients with cardiac disease often
•
CBC, urinalysis; in diabetes: blood glucose; insulin changes may be required because eating may decrease
•
Height, growth rate in children; growth rate may be decreased
•
Mental status: mood, sensorium, affect, stimulation, insomnia, irritability
Serotonin syndrome, neuroleptic malignant syndrome:
increased heart rate, shivering, sweating, dilated pupils, tremors, high B/P, hyperthermia, headache, confusion; if these occur, stop product, administer serotonin antagonist if needed; at least 2 wk should elapse between discontinuation of serotonergic agents and start of product
•
Tolerance or dependency:
increased amount of product may be used to get same effect; will develop after long-term use
•
Overdose: pain, fever, dehydration, insomnia, hyperactivity
Black Box Warning:
Before giving this product, identify presence of substance abuse; high potential for abuse
•
Gum, hard candy, frequent sips of water for dry mouth
•
Therapeutic response: increased CNS stimulation, decreased drowsiness
•
Seizures:
product may decrease seizure threshold; those with a seizure disorder should notify prescriber if seizure occurs
•
To decrease caffeine consumption (coffee, tea, cola, chocolate); may increase irritability, stimulation
•
To avoid OTC preparations unless approved by prescriber
•
To taper product over several weeks; depression, increased sleeping, lethargy may occur
•
To avoid alcohol ingestion
•
To avoid breastfeeding
•
To avoid hazardous activities until stabilized on medication
•
To get needed rest; patient will feel more tired at end of day
•
To use as part of a comprehensive treatment program
Black Box Warning:
Serious CV effects may occur from increasing dose
Administer fluids, antihypertensive for increased B/P, ammonium chloride for increased excretion, chlorproMAZINE for antagonizing CNS effects